Health
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
Publication: STAT
Author: Adam Feuerstein
Source published: 19/11/2026, 11:30:00 UTC
Briefing created: 19/11/2026, 13:20:09 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 11:36:25 UTC.
Briefings
Erasca Biotech is presenting early-stage data for ERAS-0015 at the EORTC-NCI-AACR Triple meeting in Barcelona to compete with Revolution Medicines' Rasonque for pancreatic cancer. The company claims a 40% overall response rate in second-line-plus settings, which the CEO describes as 'meaningfully different' from the current standard. The company has a $5 billion valuation, significantly lower than Revolution's $35 billion, raising speculation about a potential takeover. The evidence is limited to a press release and a single presentation at a major oncology conference.
Key points
- Erasca Biotech is presenting ERAS-0015 data at the EORTC-NCI-AACR Triple meeting in Barcelona.
- CEO Jonathan Lim signals a 40% overall response rate in second-line-plus pancreatic cancer, described as 'meaningfully different' from Rasonque.
Context
Erasca's pan-RAS inhibitor claims are backed by scant early-stage data compared to Revolution Medicines' established lead. The company's $5 billion valuation is a fraction of Revolution's $35 billion, creating speculation about a takeover. The presentation at the EORTC-NCI-AACR Triple meeting in Barcelona is the primary evidence source for these claims.
Limitations
Evidence is limited to a press release and a single presentation at a major oncology conference. No additional data, patient outcomes, or comparative trial results are provided in the source material.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 13:20:09 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeickfvxtsxcr2l53kdnrshyewlwfnly3gnkcv65zxvldbezkdy5ca4